BPI antibody (Bactericidal/Permeability Increasing Protein)

Details for Product anti-BPI Antibody No. ABIN2192029
Antigen
  • 9230105K17Rik
  • Bpifd1
  • BPIFD1
  • rBPI
  • bpi
  • bpi.L
  • lbp
  • bactericidal/permeability-increasing protein
  • bactericidal permeablility increasing protein
  • bactericidal/permeability-increasing protein S homeolog
  • BPI
  • Bpi
  • bpi.S
Reactivity
Human
107
17
9
8
Host
Mouse
92
23
1
Clonality (Clone)
Monoclonal ()
Conjugate
This BPI antibody is un-conjugated
8
5
5
5
5
4
4
3
3
3
2
2
2
2
1
1
Application
Immunoassay (IA), Flow Cytometry (FACS), Inhibition Assay (InhA)
52
28
26
22
17
10
9
8
6
6
5
2
2
2
1
1
Options
Clone 4E3
Sterility 0.2 μm filtered
Plasmids, Primers & others Plasmids, Primers & others BPI products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name Bactericidal Permeability Increasing Protein (BPI Antibody Abstract)
Background The monoclonal antibody 4E3 reacts specifically with full length human natural and recombinant Bactericidal Permeability Increasing protein (BPI). The antimicrobial protein BPI is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airways disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin. The monoclonal antibody 4E3 recognizes only free BPI and does not interact with BPI that has formed a complex with LPS.
Application Notes For flow cytometry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For neutralization of biological activity in vitro dilutions have to be made according to the amounts of BPI to be inactivated.
Restrictions For Research Use only
Buffer PBS, containing 0.1 % bovine serum albumin.
Storage 4 °C
Storage Comment Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Expiry Date 12 months
Product cited in: Dentener, Francot, Buurman: "Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes." in: The Journal of infectious diseases, Vol. 173, Issue 1, pp. 252-5, 1996 (PubMed).

Dentener, Smit, Francot, Buurman: "Characterization of two monoclonal antibodies directed against bactericidal/permeability-increasing protein." in: The Journal of infectious diseases, Vol. 170, Issue 6, pp. 1483-9, 1995 (PubMed).

Did you look for something else?